Noble Capital Markets Initiates Coverage On YS Biopharma Co with Outperform Rating, Announces Price Target of $5.25
Portfolio Pulse from Benzinga Newsdesk
Noble Capital Markets has initiated coverage on YS Biopharma Co (NASDAQ:YS) with an Outperform rating and set a price target of $5.25.

November 13, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
YS Biopharma Co received an Outperform rating from Noble Capital Markets with a price target of $5.25.
Initiation of coverage by an analyst with an Outperform rating typically signals confidence in the company's future performance and can lead to increased investor interest. The price target of $5.25 suggests a positive outlook for the stock's value, potentially influencing its short-term price movement in an upward direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100